Benefits & Risks

Zephyr Valve Treatment is Clinically Proven Safe and Effective Across Multiple Endpoints Out to At Least One Year

Zephyr Treatment Leads to Improved Health Status

Results from multiple randomized clinical trials of the Zephyr Valve have demonstrated clinically meaningful benefits in lung function, exercise capacity and Quality of Life (QoL).

 

First and only endobronchial valve clinically proven safe and effective in patients with either heterogenous or homogenous emphysema

 

Randomized Controlled TrialsSample size & follow-up periodDifference EBV vs Control Groups (ITT)
LUNG FUNCTION
(FEV1%)
EXERCISE CAPACITY
(6MWD)
QUALITY OF LIFE
(SGRQ)
LIBERATE1
2:1 Randomization
Heterogenous only
n=190
12 months
18.0%39 m-7.1 pts
TRANSFORM9
2:1 Randomization
Heterogenous only
n=97
6 months
29.3%79 m-6.5 pts
IMPACT10
1:1 Randomization
Homogenous only
n=93
6 months
16.3%28 m-7.5 pts
STELVIO11
1:1 Randomization
Heterogenous & Homogenous
n=68
6 months
17.8%74 m-14.7 pts*

*Completed Cases
Learn More About Patient Selection

Hear From an Expert

“At 3 months they [patients] get all their improvement in lung function, but their exercise tolerance continues to improve to 6 months and to a year afterward because of the reconditioning effect.”

Risks

Complications of the Zephyr Endobronchial Valve Treatment include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.